Real-World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database

PURPOSE: Elagolix is an oral gonadotropin-releasing hormone antagonist approved in the United States for the management of moderate to severe pain associated with endometriosis. We performed a real-world evaluation of the demographic and clinical characteristics of women diagnosed with endometriosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Surrey, Eric S, Soliman, Ahmed M, Johns, Beverly, Vora, Jamie B, Taylor, Hugh S, Agarwal, Sanjay K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456657/
https://www.ncbi.nlm.nih.gov/pubmed/32922052
http://dx.doi.org/10.2147/CEOR.S264905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456657/
https://www.ncbi.nlm.nih.gov/pubmed/32922052
http://dx.doi.org/10.2147/CEOR.S264905

Ejemplares similares